DE69315920T2 - Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung - Google Patents

Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung

Info

Publication number
DE69315920T2
DE69315920T2 DE69315920T DE69315920T DE69315920T2 DE 69315920 T2 DE69315920 T2 DE 69315920T2 DE 69315920 T DE69315920 T DE 69315920T DE 69315920 T DE69315920 T DE 69315920T DE 69315920 T2 DE69315920 T2 DE 69315920T2
Authority
DE
Germany
Prior art keywords
group
optionally substituted
substituted
hydrogen atom
hydrocarbon group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69315920T
Other languages
English (en)
Other versions
DE69315920D1 (de
Inventor
Hideaki Natsugari
Hitoshi Ikeda
Takenori Ishimaru
Takayuki Doi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE69315920D1 publication Critical patent/DE69315920D1/de
Publication of DE69315920T2 publication Critical patent/DE69315920T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
DE69315920T 1992-09-04 1993-09-02 Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung Expired - Fee Related DE69315920T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23748192 1992-09-04
JP10332893 1993-04-28

Publications (2)

Publication Number Publication Date
DE69315920D1 DE69315920D1 (de) 1998-02-05
DE69315920T2 true DE69315920T2 (de) 1998-06-10

Family

ID=26443975

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69315920T Expired - Fee Related DE69315920T2 (de) 1992-09-04 1993-09-02 Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung

Country Status (13)

Country Link
US (2) US5482967A (de)
EP (1) EP0585913B1 (de)
KR (1) KR940007003A (de)
CN (1) CN1090274A (de)
AT (1) ATE161530T1 (de)
AU (1) AU667739B2 (de)
CA (1) CA2105518C (de)
DE (1) DE69315920T2 (de)
FI (1) FI933857A (de)
HU (1) HUT67284A (de)
IL (1) IL106908A0 (de)
NO (1) NO179904C (de)
NZ (1) NZ248583A (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0634169B1 (de) * 1993-06-29 2000-01-05 Takeda Chemical Industries, Ltd. Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
EP0634402A1 (de) * 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinon-Derivate, ihre Herstellung und Verwendung
AU674613B2 (en) * 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
TW263498B (de) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
DE69533408T2 (de) * 1994-05-27 2005-09-08 Glaxosmithkline S.P.A. Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
US5770590A (en) * 1995-03-24 1998-06-23 Takeda Chemical Industries, Ltd. Cyclic compounds, their prudiction and use
EP0733632B1 (de) * 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten
GB9524104D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
ID18046A (id) * 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
WO1998008836A1 (fr) 1996-08-27 1998-03-05 Shionogi & Co., Ltd. Derives de chromene-3-carboxylate
KR20000057548A (ko) * 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
AU6230098A (en) * 1997-02-27 1998-09-18 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
DE19755480A1 (de) * 1997-12-13 1999-06-24 Gruenenthal Gmbh Substituierte heterocyclische Benzocycloalkene und ihre Verwendung als analgetisch wirksame Substanzen
FR2772761B1 (fr) * 1997-12-23 2000-05-26 Lipha Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant
RU2219924C2 (ru) * 1998-04-14 2003-12-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения нейропсихиатрических расстройств
RU2309953C2 (ru) 1999-11-03 2007-11-10 Эймр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
FR2801310B1 (fr) * 1999-11-24 2004-04-16 Adir NOUVEAUX DERIVES DE DIHYDROFURO-[3,4-b]QUINOLEIN-1-ONES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
BR0112350A (pt) 2000-07-11 2003-06-24 Albany Molecular Res Inc Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
PL360398A1 (en) * 2000-07-13 2004-09-06 Takeda Chemical Industries, Ltd. Lipid-rich plaque inhibitors
CA2421819C (en) * 2000-09-20 2010-03-09 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
AU2002221116A1 (en) * 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions having improved water-solubility
BR0206831A (pt) 2001-02-02 2004-07-06 Takeda Chemical Industries Ltd Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
WO2002092076A1 (en) * 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
US20040152727A1 (en) * 2001-05-18 2004-08-05 Hay Douglas William Pierre Novel use
CA2472419A1 (en) * 2002-01-11 2003-07-24 Takeda Chemical Industries, Ltd. Coumarin derivatives, process for their production and use thereof
EP1484320A1 (de) * 2002-02-13 2004-12-08 Takeda Chemical Industries, Ltd. Jnk-inhibitor
FR2849653B1 (fr) * 2003-01-08 2006-08-25 B F B Etudes Et Rech S Experim Derives de la coumarine ayant une affinite pour les recepteurs aux estrogenes, procede pour leur preparation et compositions pharmaceutiques en contenant
AU2004276238B2 (en) * 2003-09-23 2010-10-28 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
JP4719152B2 (ja) * 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノンカリウムチャネル阻害剤
WO2005046578A2 (en) * 2003-09-23 2005-05-26 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
WO2005030729A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
WO2005030791A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
US20090186874A1 (en) * 2004-01-14 2009-07-23 Yoshinori Ikeura Carboxamide derivative and use thereof
US7541478B2 (en) * 2004-03-02 2009-06-02 Takeda Pharmaceutical Company Limited Coumarin derivative and use thereof
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
DK1848430T3 (da) 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
WO2007075194A1 (en) * 2005-12-28 2007-07-05 Reddy Us Therapeutics, Inc. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
WO2006095922A1 (ja) * 2005-03-10 2006-09-14 Kyoto Pharmaceutical Industries, Ltd. テトラヒドロイソキノリン化合物およびその医薬用途
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
EP1904069B1 (de) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Aryl- und heteroarylsubstituierte tetrahydrobenzazepine und verwendung damit zur wiederaufnahmeblockierung von norepinephrin, dopamin und serotonin
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP5269086B2 (ja) * 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
CN101918365B (zh) * 2007-11-16 2013-10-09 吉联亚科学股份有限公司 人类免疫缺陷病毒复制的抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
EP2413932A4 (de) 2009-04-01 2012-09-19 Merck Sharp & Dohme Hemmer der akt-aktivität
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
NZ596104A (en) 2009-05-12 2014-01-31 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
KR20120023072A (ko) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EP2526622B1 (de) 2010-01-20 2015-09-23 Semiconductor Energy Laboratory Co. Ltd. Halbleiterbauelement
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
EP2608669B1 (de) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20120184548A1 (en) * 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
WO2013046045A1 (en) 2011-09-27 2013-04-04 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
BR112014010644A2 (pt) * 2011-11-04 2017-04-25 Hoffmann La Roche novos derivados de aril-quinolina
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (de) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8-substituierte purine als hdm2-inhibitoren
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
TWI672297B (zh) * 2013-12-18 2019-09-21 義大利商吉斯藥品公司 作為磷脂肌醇－３－激酶抑制劑之異唏衍生物
AU2016214102B2 (en) 2015-02-03 2018-09-27 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
CN106946897B (zh) * 2017-02-28 2018-10-23 牡丹江医学院 一种治疗胆囊炎的药物及其应用
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11731970B1 (en) 2023-03-23 2023-08-22 King Faisal University Pyrrolo[2,3-b]quinoline compounds as antibacterial agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509156A (en) * 1967-12-08 1970-04-28 American Home Prod 1,2-dihydro-2-oxo-3-quinolineacetamides and related intermediates
NO133758C (de) * 1970-04-04 1976-06-23 Takeda Chemical Industries Ltd
AU577105B2 (en) * 1985-04-02 1988-09-15 T.P.O. :Pharmachim: Acylaminic penicillin derivatives
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
TW205037B (de) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
JPH03181465A (ja) * 1989-12-11 1991-08-07 Takeda Chem Ind Ltd キノリン誘導体
CA2075632C (en) * 1990-02-10 2001-10-16 Kanji Meguro Chromene derivatives, their production and use
JPH059179A (ja) * 1990-09-27 1993-01-19 Takeda Chem Ind Ltd 複素環化合物、その製造法及びａｃａｔ阻害剤
ATE124408T1 (de) * 1990-10-16 1995-07-15 Takeda Chemical Industries Ltd Heterozyklische aminderivate, deren herstellung und deren verwendung.
IL99731A0 (en) * 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
EP0634402A1 (de) * 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinon-Derivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
FI933857A0 (fi) 1993-09-03
US5482967A (en) 1996-01-09
HUT67284A (en) 1995-03-28
NO933133D0 (no) 1993-09-02
HU9302499D0 (en) 1993-11-29
AU667739B2 (en) 1996-04-04
NZ248583A (en) 1995-04-27
CA2105518A1 (en) 1994-03-05
CA2105518C (en) 2005-08-09
ATE161530T1 (de) 1998-01-15
NO179904C (no) 1997-01-08
EP0585913A2 (de) 1994-03-09
NO933133L (no) 1994-03-07
DE69315920D1 (de) 1998-02-05
KR940007003A (ko) 1994-04-26
NO179904B (no) 1996-09-30
CN1090274A (zh) 1994-08-03
EP0585913A3 (en) 1994-05-25
US5700810A (en) 1997-12-23
IL106908A0 (en) 1993-12-28
EP0585913B1 (de) 1997-12-29
AU4613293A (en) 1994-03-10
FI933857A (fi) 1994-05-17

Similar Documents

Publication Publication Date Title
DE69315920D1 (de) Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung
ATE241625T1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
ATE172201T1 (de) Morphinan-derivate und medizinische verwendung
DE69023171T2 (de) Kondensierte heterozyklische Verbindungen, ihre Herstellung und Verwendung.
DE69111029D1 (de) Kondensierte heterocyclische Verbindungen, ihre Herstellung und Verwendung.
NO931529D0 (no) Cykliske fruktopyranosesulfitter og -sulfater med antikonvulsiv effekt
ATE71373T1 (de) 1,4-disubstituierte piperazin-verbindungen, ihre herstellung und ihre verwendung.
NO930974D0 (no) Fremstilling og anvendelse av triazolpyridazinforbindelser
ATE53585T1 (de) Penemverbindungen, ihre herstellung und verwendung.
DE69432542D1 (de) Tetraderivate, ihre Herstellung und Verwendung
ATE86991T1 (de) Analgetische carbonsaeureamid-derivate.
EP0979823A4 (de) Neue amidverbindungen und medikamente die diese enthalten
DE69004598T2 (de) 6-Amino-6-desoxyfumagillole, ihre Herstellung und ihre Verwendung.
ATE168376T1 (de) Triazolopyridazin-derivate, ihre herstellung und verwendung
ATE137747T1 (de) Aminobenzolverbindungen, herstellung und verwendung
DE69607890D1 (de) Aromatische Hydroxamsäure-Verbindungen, ihre Herstellung und Verwendung
ATE80162T1 (de) Antibiotisch wirkende isoxazolderivate, ihre herstellung und verwendung.
DE68907925D1 (de) Oxadiazolverbindungen, ihre herstellung und ihre verwendung als pestizide.
DE3675524D1 (de) Dem antibiotikum tan-749 aehnliche verbindungen und ihre herstellung.
FI832646A (fi) Foereningar, som har angiotensin konverterande enzym inhiberande aktivitet och diuretisk aktivitet
ATE26713T1 (de) Pyridin-pyrimidinon-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP

8339 Ceased/non-payment of the annual fee